Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 12/2015

01-12-2015 | Vasculitis (LR Espinoza, Section Editor)

Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects

Author: Rafael G. Grau

Published in: Current Rheumatology Reports | Issue 12/2015

Login to get access

Abstract

An increasing number of therapeutic agents have been associated with a vasculitic syndrome. This usually involves small vessels, primarily capillaries, venules, and arterioles in leukocytoclastic vasculitis, small-vessel disease similar to an antineutrophil cytoplasmic antibody-related vasculitis, or mid-sized muscular arteries in a polyarteritis-like picture. Antineutrophil cytoplasmic antibodies are present in many cases of vasculitis regardless of the size of the vessel involved. Monoclonal antibodies used to treat many autoimmune disorders have become the most common agents associated with drug-induced vasculitis. Important advances in epigenetics, genetics, and neutrophil apoptosis are providing new insights into the pathogenesis of both drug-induced vasculitis and idiopathic vasculitis. Although management has not changed significantly in the past few years where withdrawal of the offending agent is the primary intervention, increasing awareness of drug-induced vasculitis can lead to earlier diagnosis and prevention of severe organ damage and fatalities.
Literature
1.
2.••
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1–11. Important paper that updates the nomenclature of the vasculitides utilizing recent advances in our understanding of these conditions.CrossRefPubMed
3.
Aloush V, Litinsky I, Caspi D, Elkayam O. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Semin Arthritis Rheum. 2006;36:4–9.CrossRefPubMed
4.
ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother. 2002;36:130–47.CrossRefPubMed
5.
6.
7.
Waller R, Ahmed A, Patel I, Luqmani R. Update on the classification of vasculitis. Best Pract Res Clin Rheum. 2013;27:3–17.CrossRef
8.
Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.CrossRefPubMed
9.
Kallenberg CG. Key advances in the clinical approach to ANCA-associated vasculitis. Nat Rev Rheumatol. 2014;10:484–93.CrossRefPubMed
10.•
Radic M, Kaplan MJ. Jumbled NETs promote vasculitis. Arthritis Rheum. 2012;64:3498–501. Well-crafted editorial that describes a new form of apoptosis consisting of the formation of neutrophil extracellular nets and their possible role in the presentation of autoantigens to the immune system.CrossRefPubMed
11.
Radic M, Martinovic Kaliterna D, Radic J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med. 2012;70:12–7.PubMed
12.
Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science. 1994;266:810–3.CrossRefPubMed
13.
Denissen NH, Peters JG, Masereeuw R, Barrera P. Can sulfasalazine therapy induce or exacerbate Wegener’s granulomatosis? Scand J Rheumatol. 2008;37:72–4.CrossRefPubMed
14.
Ralston DR, Marsh CB, Lowe MP, Wewers MD. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors. J Clin Invest. 1997;100:1416–24.PubMedCentralCrossRefPubMed
15.
Altorok N, Sawalha AH. Epigenetics in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol. 2013;25:569–76.CrossRefPubMed
16.
Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol. 2006;176:7143–7.CrossRefPubMed
17.
Deng C, Lu Q, Zhang Z, Rao T, Attwood J, Yung R, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 2003;48:746–56.CrossRefPubMed
18.
Ciavatta DJ, Yang J, Preston GA, Badhwar AK, Xiao H, Hewins P, et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest. 2010;120:3209–19.PubMedCentralCrossRefPubMed
19.
Singh V, Sharma P, Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets. 2013;13:379–99.CrossRefPubMed
20.•
Pendergraft 3rd WF, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol. 2014;26:42–9. Excellent review of ANCA-related vasculitis.CrossRefPubMed
21.
Liang D, Shen N. MicroRNA involvement in lupus: the beginning of a new tale. Curr Opin Rheumatol. 2012;24:489–98.CrossRefPubMed
22.•
Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest. 2012;122:1973–90. Important introduction on the role of microRNAs in vascular inflammation and its potential importance in vasculitis.PubMedCentralPubMed
23.
Finlay AY, Statham B, Knight AG. Hydrallazine-induced necrotising vasculitis. Br Med J (Clin Res Ed). 1981;282:1703–4.CrossRef
24.
Jagiello P, Gross WL, Epplen JT. Complex genetics of Wegener granulomatosis. Autoimmun Rev. 2005;4:42–7.CrossRefPubMed
25.
Willcocks LC, Lyons PA, Rees AJ, Smith KG. The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther. 2010;12:202.PubMedCentralCrossRefPubMed
26.
Wieczorek S, Holle JU, Epplen JT. Recent progress in the genetics of Wegener’s granulomatosis and Churg-Strauss syndrome. Curr Opin Rheumatol. 2010;22:8–14.CrossRefPubMed
27.
Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214–23.PubMedCentralCrossRefPubMed
28.
Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176:231–41.PubMedCentralCrossRefPubMed
29.
Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532–5.CrossRefPubMed
30.
Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15:623–5.PubMedCentralCrossRefPubMed
31.••
Nakazawa D, Tomaru U, Suzuki A, Masuda S, Hasegawa R, Kobayashi T, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:3779–87. Important paper that describes the alterations the occur to the neutrophil extracellular traps when mice are exposed to propylthiouracil.CrossRefPubMed
32.
Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955–63.PubMedCentralCrossRefPubMed
33.
Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Maeda N, et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol. 2005;167:39–45.PubMedCentralCrossRefPubMed
34.
Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87:4115–9.PubMedCentralCrossRefPubMed
35.
Pamies A, Castro S, Poveda MJ, Fontova R. Leucocytoclastic vasculitis associated with golimumab. Rheumatology (Oxford). 2013;52:1921–3.CrossRef
36.
Parekh K, Ching D, Rahman MU, Stamp LK. Onset of Wegener’s granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event? Rheumatology (Oxford). 2010;49:1785–7.CrossRef
37.
Sakaue S, Sumitomo S, Kubo K, Fujio K, Yamamoto K. Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2014;53:1529–30.CrossRef
38.
Shibata S, Asano Y, Sato S. Cutaneous polyarteritis nodosa localized to the arm receiving an infusion of abatacept. Eur J Dermatol. 2013;23:738–9.PubMed
39.•
Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin Proc. 2012;87:739–45. Very good study comparing a single U.S. center with larger European multicenter studies of TNF inhibitors and vasculitis.PubMedCentralCrossRefPubMed
40.
Ramos-Casals M, Brito-Zeron P, Cuadrado MJ, Khamashta MA. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep. 2008;10:442–8.CrossRefPubMed
41.
Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine. 2006;73:710–3.CrossRefPubMed
42.
Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31:1955–8.PubMed
43.
Ramos-Casals M, Roberto Perez A, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents. A double-edged sword? Autoimmun Rev. 2010;9:188–93.CrossRefPubMed
44.
Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves’ disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol (Oxf). 2001;54:651–4.CrossRef
45.
Yazisiz V, Ongut G, Terzioglu E, Karayalcin U. Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. Int J Clin Pract. 2010;64:19–24.CrossRefPubMed
46.
Tu YL, Tsai YC, Huang JL, Yao TC. Occult pulmonary hemorrhage as a rare presentation of propylthiouracil-induced vasculitis. Pediatrics. 2011;127:e245–9.CrossRefPubMed
47.
Chen M, Gao Y, Guo XH, Zhao MH. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nat Rev Nephrol. 2012;8:476–83.CrossRefPubMed
48.
Tsuboi K, Ishihara Y, Ishikawa M, Tsuchida Y, Nagasawa K, Watanabe N, et al. Unusual oral ulceration, skin rash, and fever in a patient receiving propylthiouracil. Thyroid. 2009;19:421–2.CrossRefPubMed
49.
Ozkok A, Kaya S, Elcioglu OC, Odabas AR. Propylthiouracil-induced cryoglobulinemic vasculitis. Intern Med. 2013;52:2011–2.CrossRefPubMed
50.
Wakamatsu K, Mitsuhashi Y, Yamamoto T, Tsuboi R. Propylthiouracil-induced antineutrophil cytoplasmic antibody positive vasculitis clinically mimicking pyoderma gangrenosum. J Dermatol. 2012;39:736–8.CrossRefPubMed
51.
Ozkok A, Salman S, Agan M, Yavuz AS, Yarman S, Boztepe H, et al. Propylthiouracil induced anti-neutrophil cytoplasmic antibody-associated vasculitis with bone marrow plasmacytosis and granulocytopenia. Chin Med J (Engl). 2009;122:1112–4.
52.
53.
Chen YX, Zhang W, Chen XN, Yu HJ, Ni LY, Xu J, et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis versus primary ANCA-associated renal vasculitis: a comparative study. J Rheumatol. 2012;39:558–63.CrossRefPubMed
54.
Ahmed K, Rao S, Simha V. Antineutrophil cytoplasmic antibody-positive vasculitis in a patient with graves disease: cross-reaction between propylthiouracil and methimazole. Endocr Pract. 2010;16:449–51.CrossRefPubMed
55.
Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology (Oxford). 2008;47:1515–20.CrossRef
56.
Waller JM, Feramisco JD, Alberta-Wszolek L, McCalmont TH, Fox LP. Cocaine-associated retiform purpura and neutropenia: is levamisole the culprit? J Am Acad Dermatol. 2010;63:530–5.CrossRefPubMed
57.•
Khan TA, Cuchacovich R, Espinoza LR, Lata S, Patel NJ, Garcia-Valladares I, et al. Vasculopathy, hematological, and immune abnormalities associated with levamisole-contaminated cocaine use. Semin Arthritis Rheum. 2011;41:445–54. An excellent study of four cases seen at their institution followed by a thorough literature review of levamisole-contaminated cocaine use.CrossRefPubMed
58.
Wolford A, McDonald TS, Eng H, Hansel S, Chen Y, Bauman J, et al. Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: a case for reactive metabolite(s) involvement. Drug Metab Dispos. 2012;40:1067–75.CrossRefPubMed
59.
Lee BL, Stone JH, Gimbel D, Khosroshahi A. A 44-year-old woman with cutaneous bullae and extensive skin necrosis. Arthritis Care Res (Hoboken). 2010;62:1805–11.CrossRef
60.
Espinoza LR, Perez AR. Cocaine-induced vasculitis: clinical and immunological spectrum. Curr Rheumatol Rep. 2012;14:532–8.CrossRefPubMed
61.
Wiesner O, Russell KA, Lee AS, Jenne DE, Trimarchi M, Gregorini G, et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum. 2004;50:2954–65.CrossRefPubMed
62.
Magro CM, Wang X. Cocaine-associated retiform purpura: a C5b-9-mediated microangiopathy syndrome associated with enhanced apoptosis and high levels of intercellular adhesion molecule-1 expression. Am J Dermatopathol. 2013;35:722–30.CrossRefPubMed
63.•
Trimarchi M, Bussi M, Sinico RA, Meroni P, Specks U. Cocaine-induced midline destructive lesions—an autoimmune disease? Autoimmun Rev. 2013;12:496–500. The association of ANCA in patients with severe midline destructive lesions from cocaine insufflation suggests that an immune component may play an important role in the development of these lesions.CrossRefPubMed
64.
Tsai MH, Yang JH, Kung SL, Hsiao YP. Levamisole-induced myopathy and leukocytoclastic vasculitis: a case report and literature review. Dermatol Ther. 2013;26:476–80.CrossRefPubMed
65.
Olives T, Kornas RL, Cole JB. An unexpected course and late complication of cocaine-related ANCA vasculitis. Clin Toxicol. 2014;52:707–8.
66.
67.
Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum. 2000;43:405–13.CrossRefPubMed
68.
Thakur K, Bergman M, Zaveri S, Lamore R, Vashisht R, Frederique P. Hydralazine-induced vasculitis manifesting in alveolar hemorrhage. Crit Care Med. 2014;42:A1637.CrossRef
69.
Sangala N, Lee RW, Horsfield C, Goldsmith DJ. Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe. Int Urol Nephrol. 2010;42:503–6.CrossRefPubMed
70.
Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19:338–47.CrossRefPubMed
71.
O’Dell JR, Blakely KW, Mallek JA, Eckhoff PJ, Leff RD, Wees SJ, et al. Treatment of early seropositive rheumatoid arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine. Arthritis Rheum. 2001;44:2235–41.CrossRefPubMed
72.
73.•
Kermani TA, Ham EK, Camilleri MJ, Warrington KJ. Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series. Semin Arthritis Rheum. 2012;42:213–21. A single-center study of nine patients with polyarteritis nodosa-like vasculitis associated with minocycline.CrossRefPubMed
74.
Thaisetthawatkul P, Sundell R, Robertson CE, Dyck PJ. Vasculitic neuropathy associated with minocycline use. J Clin Neuromuscul Dis. 2011;12:231–4.CrossRefPubMed
75.
Lyon TD, Ferroni MC, Casella DP, D’Agostino LA, Jackman SV. Segmental testicular infarction due to minocycline-induced antineutrophil cytoplasmic antibody-positive vasculitis. Urology. 2014;84:e1–2.CrossRefPubMed
76.
Lenert P, Icardi M, Dahmoush L. ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review. Clin Rheumatol. 2013;32:1099–106.CrossRefPubMed
77.
Guillevin L, Lhote F, Amouroux J, Gherardi R, Callard P, Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Br J Rheumatol. 1996;35:958–64.CrossRefPubMed
78.
79.
Kandula P, Kouides PA. Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol. 2006;142:246–7.CrossRefPubMed
80.
Kim MJ, Kim HO, Kim HY, Park YM. Rituximab-induced vasculitis: a case report and review of the medical published work. J Dermatol. 2009;36:284–7.CrossRefPubMed
81.
Dereure O, Navarro R, Rossi JF, Guilhou JJ. Rituximab-induced vasculitis. Dermatology. 2001;203:83–4.CrossRefPubMed
82.
Arulkumaran N, Suleman R, Cecconi M, Kiely P, Chua F. Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Rheumatol. 2012;18:39–41.CrossRefPubMed
83.
Sene D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60:3848–55.CrossRefPubMed
84.
Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008;63:677–82.CrossRefPubMed
85.
86.
Cuchacovich R, Justiniano M, Espinoza LR. Churg-Strauss syndrome associated with leukotriene receptor antagonists (LTRA). Clin Rheumatol. 2007;26:1769–71.CrossRefPubMed
87.
88.
Haroon M, Devlin J. A case of ANCA-associated systemic vasculitis induced by atorvastatin. Clin Rheumatol. 2008;27 Suppl 2:S75–7.CrossRefPubMed
89.
Kalra A, Yokogawa N, Raja H, Palaniswamy C, Desai P, Zanotti-Cavazzoni SL, et al. Hydralazine-induced pulmonary-renal syndrome: a case report. Am J Ther. 2012;19:e136–8.CrossRefPubMed
90.
Gonen KA, Erfan G, Oznur M, Erdogan C. The first case of Henoch-Schonlein purpura associated with rosuvastatin: colonic involvement coexisting with small intestine. BMJ Case Rep. 2014;2014.
91.
Gunton JE, Stiel J, Caterson RJ, McElduff A. Clinical case seminar: anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endocrinol Metab. 1999;84:13–6.CrossRefPubMed
Metadata
Title
Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects
Author
Rafael G. Grau
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 12/2015
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0545-9

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits